Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Registers Facility with FDA as Medical Device Establishment

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent said today it has registered its 80,000 square-foot manufacturing facility in Cedar Creek, Texas, with the US Food and Drug Administration as a medical device establishment.

The registration is required for manufacturing diagnostic products, which the Santa Clara, Calif.-based firm said it intends to develop.

Agilent manufactures and packages a wide range of research bioreagents at the Cedar Creek facility, including enzyme-based reagents and high-fidelity oligonucleotides. It has also built separate, dedicated diagnostics space with a capability for expansion.

"Many of Agilent's proven research platforms hold potential in diagnostic markets," Robert Schueren, Agilent VP of Genomics, said in a statement. "We've made a commitment to bring improved diagnostic tools to the medical community. Having an FDA-registered manufacturing facility is yet another step in this endeavor."

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.